𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Characterization and biological evaluation of a microparticle adjuvant formulation for plasmid DNA vaccines

✍ Scribed by Robert K. Evans; De-Min Zhu; Danilo R. Casimiro; Denise K. Nawrocki; Henryk Mach; Robert D. Troutman; Aimin Tang; Shilu Wu; Stephen Chin; Colette Ahn; Lynne A. Isopi; Donna M. Williams; Zheng Xu; John W. Shiver; David B. Volkin


Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
233 KB
Volume
93
Category
Article
ISSN
0022-3549

No coin nor oath required. For personal study only.

✦ Synopsis


We describe the physiochemical characterization and immunological evaluation of plasmid DNA vaccine formulations containing a nonionic triblock copolymer adjuvant (CRL1005) in the presence and absence of a cationic surfactant, benzalkonium chloride (BAK). CRL1005 forms particles of 1-10 microns upon warming above its phase-transition temperature (approximately 6-8 degrees C) and the physical properties of the particles are altered by BAK. DNA/CRL1005 vaccines formulated with and without BAK were evaluated in rhesus macaques to determine the effect of CRL1005 and BAK on the ability of plasmid DNA to induce a cellular immune response. Immunogenicity results indicate that the addition of CRL1005 to human immunodeficiency virus-1 gag plasmid DNA formulated in phosphate-buffered saline leads to an enhancement in the gag-specific cellular immune response. Moreover, the addition of BAK to human immunodeficiency virus-1 gag plasmid DNA/CRL1005 formulations produces an additional enhancement in gag-specific cellular immunity. In vitro characterization studies of DNA/CRL1005 formulations indicate no detectable binding of DNA to CRL1005 particles in the absence of BAK, suggesting that the enhancement of cellular immunity induced by DNA/CRL1005 formulations is not due to enhanced DNA delivery. In the presence of BAK, however, results indicate that BAK binds to CRL1005 particles, producing cationic microparticles that bind DNA through electrostatic interactions. If BAK is present at the phase-transition temperature, it reduces the particle size from approximately 2 microns to approximately 300 nm, presumably by binding to hydrophobic surfaces during particle formation. Zeta potential measurements indicate that the surface charge of CRL1005-BAK particles changes from positive to negative upon DNA binding, and DNA bound to the surface of CRL1005-BAK particles was visualized by fluorescence microscopy. These results indicate that the addition of BAK to DNA/CRL1005 formulations leads to the formation of approximately 300 nm CRL1005-BAK-DNA particles that enhance the cellular immune response in rhesus monkeys.


πŸ“œ SIMILAR VOLUMES


Physical characterization and in vivo ev
✍ Jukka Hartikka; Andrew Geall; Vesselina Bozoukova; David Kurniadi; Denis Rusalov πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 612 KB

## Abstract ## Background Plasmid DNA (pDNA) vaccines have generated significant interest for the prevention or treatment of infectious diseases. Broader applications may benefit from the identification of safe and potent vaccine adjuvants. This report describes the development of a novel polymer‐

Preparation and characterization of poly
✍ Shan Liu; Michael K. Danquah; Jenny Ho; Charles Ma; Lina Wang; Ross Coppel; Gare πŸ“‚ Article πŸ“… 2009 πŸ› Wiley (John Wiley & Sons) 🌐 English βš– 253 KB

## Abstract **BACKGROUND:** A novel ultrasonic atomization approach for the formulation of biodegradable poly(lactic‐co‐glycolic acid) (PLGA) microparticles of a malaria DNA vaccine is presented. A 40 kHz ultrasonic atomization device was used to create the microparticles from a feedstock containin